In 2025, Immunovia achieved a major milestone by launching PancreaSure, a next-generation blood test for early detection of pancreatic cancer, in the United States. The company transitioned from a development-stage organization to a commercial enterprise, building momentum across clinical, regulatory, and commercial fronts.
News Published
Annual Report 2025
2025 – The year Immunovia launched PancreaSure and transitioned to a commercial company.
Reports and presentations
Here you will find annual reports, interim reports, year-end reports and presentations from capital markets days.
More news
The science behind PancreaSure
Three published studies based on blood samples from more than 2,000 patients. One conclusion: PancreaSure...
Publicerad: 21 August, 2026
Reimbursement
More than 2.7 million Americans are at high risk for pancreatic cancer, yet only about one in five who...
Publicerad: 21 August, 2026
The commercialisation of PancreaSure
In its first ten months on the market, PancreaSure was adopted by 27 U.S. high-risk surveillance programs....
Publicerad: 21 August, 2026
IR contact
Investor relations contact details at Immunovia, with information about the responsible contact person...
Publicerad: 14 August, 2026
Survey shows strong patient support for blood-based...
A new survey of 392 high-risk individuals finds that 91% are comfortable using a blood-based test like...
Publicerad: 13 August, 2026